Chemokine (C-X-C motif) receptor 4 and atypical chemokine receptor 3 regulate vascular α1-adrenergic receptor function

Molecular Medicine

Volumn 20, Issue JULY-DECEMBER 2014, 2014, Pages 435-447

  Nevins, Amanda M ^b   Volkman, Brian F ^b   Majetschak, Matthias ^a,a   Gamelli, Richard L ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; CALCIUM CHANNEL; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR AGONIST; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; ENDOTHELIN RECEPTOR; PLERIXAFOR; PROTEIN ACKR3; STROMAL CELL DERIVED FACTOR 1; UBIQUITIN; UNCLASSIFIED DRUG; ADRENERGIC RECEPTOR STIMULATING AGENT; CHEMOKINE RECEPTOR CXCR; CMKOR1 PROTEIN, RAT; CXCR4 PROTEIN, RAT; HETEROCYCLIC COMPOUND; LIGAND; OLIGOPEPTIDE; PHENYLEPHRINE; TC14012;

ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RESPONSE; HEART FUNCTION; HEART HEMODYNAMICS; HEMORRHAGIC SHOCK; IN VIVO STUDY; MALE; MYOGRAPHY; NONHUMAN; RAT; SHOCK; VASCULAR ENDOTHELIUM; VASOCONSTRICTION; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD PRESSURE; DRUG EFFECTS; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CELL; IN VITRO STUDY; LEWIS RAT; MESENTERIC ARTERY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADRENERGIC AGONISTS; ANIMALS; BLOOD PRESSURE; CHEMOKINE CXCL12; HETEROCYCLIC COMPOUNDS; IN VITRO TECHNIQUES; LIGANDS; MALE; MESENTERIC ARTERIES; MYOCYTES, CARDIAC; OLIGOPEPTIDES; PHENYLEPHRINE; RATS, INBRED LEW; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, CXCR; RECEPTORS, CXCR4; SHOCK, HEMORRHAGIC; UBIQUITIN; VASOCONSTRICTION; VENTRICULAR FUNCTION, LEFT;

EID: 84921947993     PISSN: 10761551     EISSN: 15283658     Source Type: Journal    
DOI: 10.2119/molmed.2014.00101     Document Type: Article

References (68)

1. Bachelerie F, et al. (2013) International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol. Rev. 66:1–79; erratum 66:467.
2. Tachibana K, et al. (1998) The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature. 393:591–4.
3. Gerrits H, et al. (2008) Early postnatal lethality and cardiovascular defects in CXCR7-deficient mice. Genesis. 46:235–45.
4. Nagasawa T, et al. (1996) Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature. 382:635–8.
5. Sierro F, et al. (2007) Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7. Proc. Natl. Acad. Sci. U. S. A. 104:14759–64.
6. Bleul CC, et al. (1996) The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature. 382:829–33.
7. Balabanian K, et al. (2005) The chemokine SDF-1/ CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. J. Biol. Chem. 280:35760–6.
8. Teicher BA, Fricker SP. (2010) CXCL12 (SDF-1)/ CXCR4 pathway in cancer. Clin. Cancer Res. 16:2927–31.
9. Nagasawa T, Tachibana K, Kishimoto T. (1998) A novel CXC chemokine PBSF/SDF-1 and its receptor CXCR4: their functions in development, hematopoiesis and HIV infection. Semin. Immunol. 10:179–85.
10. Rajagopal S, et al. (2010) Beta-arrestin- but not G protein-mediated signaling by the “decoy” receptor CXCR7. Proc. Natl. Acad. Sci. U. S. A. 107:628–32.
11. Boldajipour B, et al. (2008) Control of chemokineguided cell migration by ligand sequestration. Cell. 132:463–73.
12. Kumar R, et al. (2012) CXCR7 mediated Giá independent activation of ERK and Akt promotes cell survival and chemotaxis in T cells. Cell. Immunol. 272:230–41.
13. Regard JB, Sato IT, Coughlin SR. (2008) Anatomical profiling of G protein-coupled receptor expression. Cell. 135:561–71.
14. Tripathi A, Davis JD, Staren DM, Volkman BF, Majetschak M. (2013) CXC chemokine receptor 4 signaling upon co-activation with stromal cellderived factor-1alpha and ubiquitin. Cytokine. 65:121–5.
15. LaRocca TJ, et al. (2010) â2-Adrenergic receptor signaling in the cardiac myocyte is modulated by interactions with CXCR4. J. Cardiovasc. Pharmacol. 56:548–59.
16. Agarwal U, et al. (2010) Role of cardiac myocyte CXCR4 expression in development and left ventricular remodeling after acute myocardial infarction. Circ. Res. 107:667–76.
17. Levoye A, Balabanian K, Baleux F, Bachelerie F, Lagane B. (2009) CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling. Blood. 113:6085–93.
18. Saini V, Marchese A, Majetschak M. (2010) CXC chemokine receptor 4 is a cell surface receptor for extracellular ubiquitin. J. Biol. Chem. 285:15566–76.
19. Majetschak M, Cohn SM, Nelson JA, Burton EH, Obertacke U, Proctor KG. (2004) Effects of exogenous ubiquitin in lethal endotoxemia. Surgery. 135:536–43.
20. Baker TA, Romero J, Bach HHt, Strom JA, Gamelli RL, Majetschak M. (2012) Effects of exogenous ubiquitin in a polytrauma model with blunt chest trauma. Crit. Care Med. 40:2376–84.
21. Bach Iv HH, Saini V, Baker TA, Tripathi A, Gamelli RL, Majetschak M. (2012) Initial assessment of the role of CXC chemokine receptor 4 after polytrauma. Mol. Med. 18:1056–66.
22. Bodart V, et al. (2009) Pharmacology of AMD3465: a small molecule antagonist of the chemokine receptor CXCR4. Biochem. Pharmacol. 78:993–1000.
23. Chu PY, et al. (2011) CXCR4 antagonism attenuates the cardiorenal consequences of mineralocorticoid excess. Circ. Heart Fail. 4:651–8.
24. Yu L, Hales CA. (2011) Effect of chemokine receptor CXCR4 on hypoxia-induced pulmonary hypertension and vascular remodeling in rats. Respir. Res. 12:21.
25. Zabel BA, et al. (2009) Elucidation of CXCR7-mediated signaling events and inhibition of CXCR4- mediated tumor cell transendothelial migration by CXCR7 ligands. J. Immunol. 183:3204–11.
26. Sartina E, et al. (2012) Antagonism of CXCR7 attenuates chronic hypoxia-induced pulmonary hypertension. Pediatr. Res. 71:682–8.
27. Veldkamp CT, Seibert C, Peterson FC, Sakmar TP, Volkman BF. (2006) Recognition of a CXCR4 sulfotyrosine by the chemokine stromal cell-derived factor-1alpha (SDF-1alpha/CXCL12). J. Mol. Biol. 359:1400–9.
28. Veldkamp CT, et al. (2008) Structural basis of CXCR4 sulfotyrosine recognition by the chemokine SDF-1/CXCL12. Sci. Signal. 1:ra4.
29. Veldkamp CT, et al. (2009) Monomeric structure of the cardioprotective chemokine SDF-1/CXCL12. Protein Sci. 18:1359–69.
30. Takekoshi T, Ziarek JJ, Volkman BF, Hwang ST. (2012) A locked, dimeric CXCL12 variant effectively inhibits pulmonary metastasis of CXCR4- expressing melanoma cells due to enhanced serum stability. Mol. Cancer Ther. 11:2516–25.
31. (1985) Bacterial endotoxins/pyrogens [Internet]. Silver Spring (MD): FDA; [cited 2014 Aug 29]. (Inspection technical guide). Available from: http://www.fda.gov/ICECI/Inspections/InspectionGuides/InspectionTechnicalGuides/ucm072918.htm (web page last updated 2009 Feb 17).
32. Committee for the Update of the Guide for the Care and Use of Laboratory Animals, Institute for Laboratory Animal Research, Division on Earth and Life Studies, National Research Council of the National Academies. (2011) Guide for the Care and Use of Laboratory Animals. 8th edition. Washington (DC): National Academies Press.
33. Henderson KK, Byron KL. (2007) Vasopressininduced vasoconstriction: two concentrationdependent signaling pathways. J. Appl. Physiol. 102:1402–9.
34. Brueggemann LI, Mackie AR, Mani BK, Cribbs LL, Byron KL. (2009) Differential effects of selective cyclooxygenase-2 inhibitors on vascular smooth muscle ion channels may account for differences in cardiovascular risk profiles. Mol. Pharmacol. 76:1053–61.
35. Brueggemann LI, Mani BK, Haick J, Byron KL. (2012) Exploring arterial smooth muscle Kv7 potassium channel function using patch clamp electrophysiology and pressure myography. J. Vis. Exp. 14:e4263.
36. Mani BK, Brueggemann LI, Cribbs LL, Byron KL. (2011) Activation of vascular KCNQ (Kv7) potassium channels reverses spasmogen-induced constrictor responses in rat basilar artery. Br. J. Pharmacol. 164:237–49.
37. Dow JW, Harding NG, Powell T. (1981) Isolated cardiac myocytes. I. Preparation of adult myocytes and their homology with the intact tissue. Cardiovasc. Res. 15:483–514.
38. Govindan S, et al. (2012) Pathogenic properties of the N-terminal region of cardiac myosin binding protein-C in vitro. J. Muscle Res. Cell Motil. 33:17–30.
39. Jin CZ, et al. (2013) Myofilament Ca desensitization mediates positive lusitropic effect of neuronal nitric oxide synthase in left ventricular myocytes from murine hypertensive heart. J. Mol. Cell. Cardiol. 60:107–15.
40. Geng Q, et al. (2009) A subset of 26S proteasomes is activated at critically low ATP concentrations and contributes to myocardial injury during cold ischemia. Biochem. Biophys. Res. Commun. 390:1136–41.
41. Bach HHt, Laporte HM, Wong YM, Gamelli RL, Majetschak M. (2013) Proteasome inhibition prolongs survival during lethal hemorrhagic shock in rats. J. Trauma Acute Care Surg. 74:499–507.
42. Saini V, et al. (2011) The CXC chemokine receptor 4 ligands ubiquitin and stromal cell-derived factor- 1á function through distinct receptor interactions. J. Biol. Chem. 286:33466–77.
43. Hatse S, Princen K, Bridger G, De Clercq E, Schols D. (2002) Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett. 527:255–62.
44. Gravel S, et al. (2010) The peptidomimetic CXCR4 antagonist TC14012 recruits beta-arrestin to CXCR7: roles of receptor domains. J. Biol. Chem. 285:37939–43.
45. Majetschak M, Cohn SM, Obertacke U, Proctor KG. (2004) Therapeutic potential of exogenous ubiquitin during resuscitation from severe trauma. J. Trauma. 56:991–9.
46. O’Boyle G, Mellor P, Kirby JA, Ali S. (2009) Antiinflammatory therapy by intravenous delivery of non-heparan sulfate-binding CXCL12. FASEB J. 23:3906–16.
47. Misra P, et al. (2008) Quantitation of CXCR4 expression in myocardial infarction using 99mTc-labeled SDF-1alpha. J. Nucl. Med. 49:963–9.
48. Burns JM, et al. (2006) A novel chemokine recep- tor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J. Exp. Med. 203:2201–13.
49. Berahovich RD, Penfold ME, Schall TJ. (2010) Nonspecific CXCR7 antibodies. Immunol. Lett. 133:112–4.
50. Majetschak M. (2011) Extracellular ubiquitin: immune modulator and endogenous opponent of damage-associated molecular pattern molecules. J. Leukoc. Biol. 89:205–19.
51. Butera D, et al. (2005) Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. Blood. 106:1175–82.
52. Derdeyn CA, et al. (1999) Correlation between circulating stromal cell-derived factor 1 levels and CD4+ cell count in human immunodeficiency virus type 1-infected individuals. AIDS Res. Hum. Retroviruses. 15:1063–71.
53. Kieffer AE, et al. (2003) The N- and C-terminal fragments of ubiquitin are important for the antimicrobial activities. Faseb J. 17:776–8.
54. Hendrix CW, et al. (2000) Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob. Agents Chemother. 44:1667–73.
55. Widney DP, Xia YR, Lusis AJ, Smith JB. (2000) The murine chemokine CXCL11 (IFN-inducible T cell alpha chemoattractant) is an IFN-gammaand lipopolysaccharide-inducible glucocorticoid- attenuated response gene expressed in lung and other tissues during endotoxemia. J. Immunol. 164:6322–31.
56. Moore CA, Milano SK, Benovic JL. (2007) Regulation of receptor trafficking by GRKs and arrestins. Annu. Rev. Physiol. 69:451–82.
57. Busillo JM, Benovic JL. (2007) Regulation of CXCR4 signaling. Biochim. Biophys. Acta. 1768:952–63.
58. Marchese A, Chen C, Kim YM, Benovic JL. (2003) The ins and outs of G protein-coupled receptor trafficking. Trends Biochem. Sci. 28:369–76.
59. Rockman HA, Koch WJ, Lefkowitz RJ. (2002) Seven-transmembrane-spanning receptors and heart function. Nature. 415:206–12.
60. Diviani D, et al. (1996) Effect of different G protein- coupled receptor kinases on phosphorylation and desensitization of the alpha1B-adrenergic receptor. J. Biol. Chem. 271:5049–58.
61. Collins S, Bouvier M, Lohse MJ, Benovic JL, Caron MG, Lefkowitz RJ. (1990) Mechanisms involved in adrenergic receptor desensitization. Biochem. Soc. Trans. 18:541–4.
62. McGraw DW, et al. (2006) Airway smooth muscle prostaglandin-EP1 receptors directly modulate beta2-adrenergic receptors within a unique heterodimeric complex. J. Clin. Invest. 116:1400–9.
63. Dzimiri N. (2002) Receptor crosstalk. Implications for cardiovascular function, disease and therapy. Eur. J. Biochem. 269:4713–30.
64. Milligan G, Canals M, Pediani JD, Ellis J, Lopez- Gimenez JF. (2006) The role of GPCR dimerisation/ oligomerisation in receptor signalling. Ernst Schering Found. Symp. Proc. 2:145–61.
65. Stanasila L, Perez JB, Vogel H, Cotecchia S. (2003) Oligomerization of the alpha 1a- and alpha 1badrenergic receptor subtypes. Potential implications in receptor internalization. J. Biol. Chem. 278:40239–51.
66. Mustafa S, et al. (2012) Identification and profiling of novel alpha1A-adrenoceptor-CXC chemokine receptor 2 heteromer. J. Biol. Chem. 287:12952–65.
67. Schols D, Struyf S, Van Damme J, Este JA, Henson G, De Clercq E. (1997) Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J. Exp. Med. 186:1383–8.
68. Kalatskaya I, Berchiche YA, Gravel S, Limberg BJ, Rosenbaum JS, Heveker N. (2009) AMD3100 is a CXCR7 ligand with allosteric agonist properties. Mol. Pharmacol. 75:1240–7.